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Abstract Alzheimer’s disease (AD) is the most common
cause of dementia in the elderly, with a prevalence of 5 %
after 65 years of age, increasing to about 30 % in people
aged 85 years or older. It is characterized by progressive
cognitive impairment, including impaired judgment, deci-
sion-making and orientation, and in some cases accompa-
nied by psycho behavioral disturbances or language
impairment. Herein, we summarize and discuss the main
articles describing novel findings in AD published over the
last year, including clinical, therapeutic, and research issues.
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Introduction
Alzheimer’s disease (AD) is the most common cause of
dementia in the elderly, with a prevalence of 5 % after
65 years of age, increasing to about 30 % in people aged
85 years or older. It is characterized by progressive cog-
nitive impairment, including impaired judgment, decision-
making, and orientation is some cases accompanied by
psycho behavioral disturbances or language impairment.
Mutations in genes encoding for amyloid precursors pro-
tein (APP), presenilin 1 (PSEN1), and presenilin 2
(PSEN2) account for about 3 % of cases, characterized by
an early onset (even in the third or fourth decade of life),
whereas the majority of cases is sporadic, likely caused by
the interaction of genetic and environmental factors.
The two major neuropathology hallmarks of AD are
extracellular amyloid beta (Ab) plaques and intracellular
neurofibrillary tangles (NFTs). The production of Ab,
which represents a crucial step in AD pathogenesis, is the
result of cleavage of the APP, which is over-expressed in
AD [1]. Ab forms highly insoluble and proteolysis resistant
fibrils known as senile plaques (SP). NFTs are instead
composed of the tau protein. In healthy subjects, tau is a
component of microtubules, which represent the internal
support structures for the transport of nutrients, vesicles,
and mitochondria within the cell. Microtubules stabilize
growing axons, which are necessary for the development
and growth of neurites [1]. In AD, tau protein is abnor-
mally hyperphosphorylated and forms insoluble fibrils,
originating NFTs into the cell.
In the last few years, biomarkers for an early diagnosis
and treatment have been discovered and validated,
including cerebrospinal fluid (CSF) Ab, tau, and phos-
phorylated tau (Ptau), structural and functional imaging.
These new discoveries have been incorporated in novel
criteria for the diagnosis of AD [2, 3].
Herein, we summarize and discuss the main articles
describing novel findings in AD published over the last
year, including clinical, therapeutic, and research issues.
Clinical aspects and biomarkers
Epidemiology, diagnosis, and biomarkers
Among risk factors for dementia, it was shown that delir-
ium is a strong risk factor in a large oldest-old population
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[4]. Fixed- and random-effects regression models were
used to assess the association between delirium and inci-
dent dementia and decline in mini mental state examination
(MMSE) scores. Results showed that delirium increased
the risk of incident dementia (OR = 8.7) and was associ-
ated with the worsening of dementia severity (OR = 3.1)
as well as with the deterioration in global function score
(OR = 2.8) [4].
Prioni et al. [5] investigated stereotypy frequency and
type in patients with AD, behavioral variant frontotemporal
dementia (bvFTD), progressive supranuclear palsy, and
Parkinson’s disease dementia, demonstrating that AD
patients have fewer stereotypes than the other groups.
Buchhave et al. [6] assessed the ability of the CSF
biomarkers Ab, Ptau to predict the development of AD by
analyzing these proteins in a cohort of subjects with mild
cognitive impairment (MCI) followed-up clinically for
5–10 years. Baseline CSF Ab levels were reduced in both
patients who converted to AD in 0–5 years (early con-
verters) and in those who converted in 5–10 years (late
converters), whereas tau and Ptau levels were altered in
early, but not in late, converters. Overall, 90 % of patients
with MCI and pathologic biomarker values at baseline
develop AD within 10 years [6]. Implications coming from
this study include that (1) studies with a shorter follow-up
will underestimate the positive predictive value and the
specificity of CSF biomarkers, (2) patients with pathologic
biomarkers should be selected for clinical trials with novel
disease-modifying drugs, (3) Patients diagnosed with MCI
with normal CSF biomarkers would most likely not need
extensive and costly follow-up.
Regarding CSF biomarkers for AD diagnosis, Mattsson
et al. [7] demonstrated that, although the diagnostic accu-
racies for AD decrease with age, the predictive value for a
combination of biomarkers remain stable, whereas the
negative predictive value decreases slightly in old subjects,
due to the high AD prevalence in older ages. To predict
instead time to dementia in patients with MCI and evidence
of amyloid pathology, injury markers, including abnormal
CSF tau, abnormal CSF Ptau, and hippocampal atrophy,
are likely more useful than other biomarkers [8].
In an attempt to identify peripheral biomarkers for AD,
Llano et al. [9] performed a multivariate analysis of 146
plasma analytes in a large cohort of patients with AD or
MCI as compared with elderly controls. They identified
four different proteomic signatures, each composed of
5–14 analytes that differentiate AD from controls with
sensitivity and specificity ranging from 74 to 85 %. Five
analytes, including apolipoprotein A-II, apolipoprotein E,
serum glutamic oxaloacetic transaminase, a-1-microglob-
ulin, and natriuretic peptide, were common to all signa-
tures. Unfortunately, none of these predicted the
conversion from MCI to AD [9]. A similar approach was
carried out by Soares et al. [10], who showed increased
plasma levels of eotaxin 3, pancreatic polypeptide, and
N-terminal protein B-type brain natriuretic peptide in
patients with AD, in line with previous observations in
CSF. In addition, increases in tenascin C levels and
decreases in IgM and apolipoprotein (Apo)E levels were
also observed. Notably, patients carrying an ApoE e4
allele showed a distinct profile, characterized by low
C-reactive protein and ApoE levels and high cortisol,
interleukin 13, apolipoprotein B, and c-interferon levels,
thus highlighting the importance of genotype on blood
protein profiles [10].
Among candidate biomarkers, molecules related to
DNA damage and telomere dysfunction, including chiti-
nase activity, N-acetyl-glucosaminidase activity, stathmin
and EF-1a, were studied in CSF from AD patients as
compared with controls and patients with non-AD
dementia. Watabe-Rudolph et al. [11] showed that enzy-
matic activity of chitinase and stathmin protein levels were
significantly increased in CSF from patients, both with AD
or non-AD dementia, compared with controls. As single
marker, chitinase distinguished patients with dementia
from no dementia with an accuracy of 85.8 %. In another
study [12], CSF proteomic changes were analyzed in
familial and sporadic AD as compared with non-demented
subjects. The authors found overlap between familial cases,
both presymptomatic and symptomatic, and sporadic ones.
Fourteen proteins altered were previously reported in other
studies, including amyloid precursor protein, transferrin,
a(1)b-glycoprotein, complement components, afamin pre-
cursor, spondin 1, plasminogen, hemopexin, and neuronal
pentraxin receptor, whereas others were unique to this
study, including calsyntenin 3, AMPA (a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid) 4 glutamate
receptor, CD99 antigen, di- N-acetyl-chitobiase, and
secreted phosphoprotein 1.
Familial Alzheimer’s disease
Familial AD (FAD) is considered the best study model for
understanding the pathogenesis of the disease, particularly
to elucidate mechanisms occurring before the appearance
of symptoms. In line with this, Bateman et al. [13] studied
128 subjects of families with a FAD autosomal dominant
mutation in amyloid precursor protein or presenilin genes,
including symptomatic and asymptomatic carriers as well
as non-carriers, on the basis that results obtained in FAD
could be translated to sporadic AD. They demonstrated that
biomarkers known so far change very early during the
pathogenesis. In particular, variations occur as follows:
– CSF Ab levels start dropping 25 years before occur-
rence of symptoms.
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– Ab deposition, measured by positron-emission tomog-
raphy (PET) with the use of Pittsburgh compound B,
was detected 15 years before expected symptom onset.
– Increased concentrations of CSF tau levels and an
increase in brain atrophy at magnetic resonance imag-
ing (MRI) were detected 15 years before expected
symptom onset.
– Cerebral hypometabolism on PET and impaired epi-
sodic memory were observed 10 years before expected
symptom onset.
– Global cognitive impairment, measured by the MMSE
and the Clinical dementia rating scale (CDR), was
detected 5 years before expected symptom onset.
These findings imply that the targeting of Ab earlier in
the course of the disease may provide better clinical out-
comes than the treatment of mild to moderate dementia
(phases in which the neuronal and synaptic loss has already
occurred). Moreover, they suggest that secondary preven-
tion trials, which are designed to prevent or delay cognitive
and clinical impairment, may ultimately test the Ab
hypothesis, just as the cholesterol hypothesis of heart dis-
ease was tested three decades ago. Nevertheless, the cur-
rent analyses are based on cross-sectional data, and thus
need to be confirmed by studying individual longitudinal
changes.
On the basis of the previous considerations, Reiman
et al. [14] followed-up 44 young adults from the Colom-
bian Alzheimer’s Prevention Initiative Registry in Mede-
llı´n Antioquia (Colombia), including 20 PSEN1 E280A
mutation carriers and 24 non-carriers. They underwent
neuropsychological testing, lumbar puncture and venous
puncture, and structural and functional MRI. Young adults
at genetic risk for autosomal dominant FAD had functional
and structural MRI findings, as well as CSF and plasma
biomarkers consistent with Ab(1–42) overproduction.
Therefore, this study demonstrates that more than two
decades before the estimated age at MCI onset (44 years)
and at full-blown dementia (49 years), functional and
structural MRI changes are detectable in young adult
PSEN1 E280A mutation carriers, along with CSF and
plasma biomarker findings that suggest Ab(1–42) increased
production.
Joshi et al. [15] compared clinical characteristics
between FAD and non-familial early onset AD (NF-EAD),
aiming to identify clinical features that suggest a genetic
origin of the disease and that thus suggest to go on with the
genetic counseling. Patients carrying a PSEN1 mutation
had an earlier age at disease onset as compared with non-
carriers (41.8 versus 55.9 years), and, at initial assessment,
longer disease duration and lower MMSE scores. Patients
with NF-EAD were more likely to present with non-
memory deficit. FAD patients were instead more likely to
have headaches, myoclonus, and gait abnormalities.
Therapeutic aspects
In the last few years, a number of claimed ‘‘disease-mod-
ifying’’ compounds, mainly aimed to prevent or remove
Ab, have been developed and tested in double-blind, pla-
cebo-controlled clinical trials.
In this framework, Winblad et al. [16] reported results of a
phase I, double-blind, placebo-controlled, 52-week study
with CAD106 (Novartis), carried out in two centers in
Sweden. CAD106 is the first second-generation vaccine. It
presents multiple copies of Ab1-6 peptide derived from the
N-terminal B cell epitope of Ab that avoids T cell activation,
coupled to the Qb virus-like particle. In animals, CAD106
induced Ab-antibody titers without activating Ab-reactive
T-cells. In this trial, 58 patients with mild to moderate AD,
aged 50–80 years, were entered into one of two cohorts
according to time of study entry, and then randomly allocated
to receive either CAD 106 or placebo (ratio 4:1; the first
cohort, consisting of 31 patients, received CAD106 50 lg or
placebo; the second, consisting of 27 patients, received
CAD106 150 lg or placebo). Each patient received three
subcutaneous injections. Primary objectives were to assess
safety and tolerability of CAD106 and to identify Ab-anti-
body response (patients with Ab-IgG serum titers[16 units
at least once during the study were considered responders).
Almost all patients (56/58) reported adverse events. The
most common side effect in cohort 1 was nasopharyngitis,
whereas is in cohort 2 was injection site erythema. No cases
of clinical or subclinical cases of meningoencephalitis were
observed. Sixty-seven percent of CAD106-treated patients
in cohort I and 82 % in cohort 2 developed Ab antibody
response. However, also one placebo-treated patient out of
12 had Ab-IgG concentrations that qualified them as
responder. In conclusion, results of these trials suggest that
CAD106 has a favorable safety profile and acceptable anti-
body response in patients with AD [17]. Additional vaccines
are under testing (see [17] for review).
A randomized, double-blind, placebo-controlled, clini-
cal trial with antioxidants has recently been carried out in
AD [18]. Patients with mild to moderate AD were ran-
domly assigned to treatment for 16 weeks with 800 IU/day
of vitamin E (a-tocopherol) plus 500 mg/day of vitamin C
plus 900 mg/day of a-lipoic acid (E/C/ALA); 400 mg of
coenzyme Q 3 times/day; or placebo. Outcomes included
changes in CSF biomarkers and cognition. Results showed
that antioxidant treatments did not alter CSF biomarker and
did not influence cognition.
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Jeppsson et al. [19] identified, using fragment-based
screening and structure-based design, a potent and selective
inhibitor of human BACE1, named AZD3839 potentially
useful for treating AD. They studied its effect, together
with pharmacokinetic/pharmacodynamic analyses, in
mouse and guinea pig. Results suggest that this compound
has disease-modifying potential in the treatment of AD and
it has been progressed into phase I clinical trials in men.
Research aspects
Tartaglia et al. [20] assessed the relative contribution of
white matter (WM) and gray matter (GM) abnormalities to
cognitive dysfunction in patients with AD and bvFTD,
demonstrating that reduced integrity of specific WM tracts
contribute to cognitive deficits observed in bvFTD patients,
after accounting for GM atrophy. In AD instead, memory
impairment was related to WM tract injury, but this rela-
tionship was no longer observed when GM volumes were
included.
Regarding brain changes occurring during AD patho-
genesis, La Joie et al. [21] demonstrated, by using struc-
tural MRI, (18)F-fluorodeoxyglucose PET, and (18)F-
florbetapir PET (an amyloid tracer) that there is a region-
specific hierarchy between atrophy, hypometabolism and
Ab load in AD. In particular, in the hippocampus, atrophy
exceeded hypometabolism, whereas Ab load was minimal;
in posterior association areas, Ab deposition was predom-
inant, together with marked hypometabolism and lower but
still significant atrophy; in frontal regions, Ab deposition
was maximal, whereas structural and metabolic alterations
were low.
Regarding in vivo models, Lee et al. [22] analyzed
micro(mi)RNA-206 expression in Tg2576 transgenic mice
and human AD brain samples. They demonstrated that
mouse brains and the temporal cortex of human AD brains
had increased levels of miR-206, which targets brain-
derived neurotrophic factor (BDNF) transcripts.
New findings on the role of tau protein have been
described by Tai et al. [23], who demonstrated that, in
addition to its well-described axonal localization, tau is
present at both presynaptic and postsynaptic terminals in
normal human brains. In AD, tau becomes hyperphos-
phorylated and misfolded at both terminals, and the accu-
mulation of hyperphosphorylated oligomers at synapses is
associated with increased ubiquitinated substrates and
increased proteasome components, consistent with dys-
function of the ubiquitin–proteasome system. In addition,
Saman et al. [24] demonstrated that exosome-associated
tau is present in human CSF, and is phosphorylated at Thr-
181, suggesting that exosome-mediated secretion of phos-
phorylated tau may play a role in the abnormal processing
of tau and in the genesis of elevated tau levels in CSF in
early AD.
Regarding basic research, Israel et al. [25] developed a
new model for studying AD by reprogramming primary
cells from patients into induced pluripotent stem cells
(iPSCs). In particular, they reprogrammed fibroblasts from
two patients with familial AD, two with sporadic AD and
two non-demented controls into iPSCs lines and obtained
purified cultures with more than 90 % neurons. Relative to
controls, iPSC-derived neurons from patients exhibited
significantly higher levels of the pathological markers
Ab(1–40), Ptau(Thr231) and active glycogen synthase
kinase-3b (aGSK-3b).
Another field of research possibly explaining the com-
plexity of AD concerns the role of epigenetic alterations. In
this regard, Marques et al. [26] demonstrated that BACE1
mRNA levels are increased in the aged triple transgenic
animal model of AD (3xTg-AD) as well as in peripheral
blood mononuclear cells (PMBC) from AD patients, along
with an increase in promoter accessibility and histone H3
acetylation, while BACE1 promoter region was less
accessible in PBMC from MCI individuals.
Final remarks
AD is the most common and the most studied neurode-
generative disorder. Results of the last year, as well as
previous findings, lead to an increased knowledge of
pathogenic events at the basis of the disease, with potential
implications for future treatments. In this regard, a crucial
point that emerged is that disease-modifying treatments for
AD could be effective only in certain phases of the disease,
particularly in mild stages. Therefore, an early diagnosis is
advisable, even before symptoms occur. To do so, vali-
dated biomarkers have been included in the clinical
workup, including CSF and imaging analysis, as well as
genetics. Concerning genetically determined AD, it has
become clearer and clearer that such cases represent the
best model for testing the efficacy of new drugs, and
clinical trials on a large Colombian population of mutation
carriers is already ongoing, hopefully opening the way to
early preventive treatments.
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